Close Menu

Boehringer-Ingelheim

Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.

Under the agreement, Israel’s BiomX will generate metagenomic data for gut microbiome samples from IBD patients using its XMarker biomarker discovery platform. 

Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.

The firms are focusing on developing a rapid diagnostic test for African swine fever that can be used on GNA's portable MDx platform.

An extended labeling claim has added detection of three additional EGFR mutations to help ID NSCLC patients for whom Boehringer Ingelheim's Gilotrif is indicated.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

In head-to-head studies, a next-generation EGFR inhibitor and an ALK inhibitor beat their older counterparts in staving of cancer progression.  

The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.

The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis. 

Poor patient health, tumor histology, insufficient tissue samples, and long turnaround times are some reasons doctors gave for not using EGFR status to determine care.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.